Utama › Kegagalan Ginjal › Pennsylvania
Kajian klinikal Kegagalan Ginjal di Pennsylvania
7 kajian untuk Kegagalan Ginjal sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Northeast Clinical Research Center, LLC, Bethlehem
- Clinical Renal Associates, LTD, Exton
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05485961A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
- Research Site, Bethlehem
Mengambil pesertaFasa 1/2Sukarelawan sihat dialu-alukan
Umur 18 hingga 55 · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT06749457Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- Butler Memorial Hospital, Butler
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT04634916Virtual Reality in End Stage Kidney Disease
- University of Pennsylvania, Philadelphia
Mengambil peserta
Semua umur · Semua jantina · Dikemas kini 10 Jul 2026 · NCT06356168PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
- University Pittsburgh Medical Center, Pittsburgh
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jun 2026 · NCT06422871Kidney Transplant Improvement Through New Exercise Training to Increase Capacity
- Perelman Center for Advanced Medicine, Philadelphia
Mengambil peserta
Umur 60 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT07446296A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- Guthrie Clinic, Sayre
Mengambil peserta
Umur 18 hingga 90 · Semua jantina · Dikemas kini 22 Dis 2025 · NCT04671771Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.